Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-masked trial of SOK583A1 vs Eylea in neovascular age-related macular degeneration
jRCT2031210120Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Nov 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 in exudative macular degeneration (2 arms), sponsored by Hexal AG. Primary endpoints: Mean change from baseline in BCVA score using ETDRS testing charts at Week 8, Spectral Domain Optical Coherence Tomography (SD-OCT) parameters and 1 more. Started Nov 2021; status: completed.
02
Drugs
9MW0813
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031210120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210120.